Literature DB >> 30355155

Molecular Pathogenesis of the Tauopathies.

Jürgen Götz1, Glenda Halliday2, Rebecca M Nisbet1.   

Abstract

The tauopathies constitute a group of diseases that have Tau inclusions in neurons or glia as their common denominator. In this review, we describe the biochemical and histological differences in Tau pathology that are characteristic of the spectrum of frontotemporal lobar degeneration as primary tauopathies and of Alzheimer's disease as a secondary tauopathy, as well as the commonalities and differences between the familial and sporadic forms. Furthermore, we discuss selected advances in transgenic animal models in delineating the different pathomechanisms of Tau.

Entities:  

Keywords:  AD; Alzheimer's disease; FTLD; frontotemporal lobar degeneration; microtubule-associated protein Tau; neuropathology; signaling cascade; tauopathy

Mesh:

Substances:

Year:  2018        PMID: 30355155     DOI: 10.1146/annurev-pathmechdis-012418-012936

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  43 in total

1.  Incidence and Trends of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Population-Based Study.

Authors:  Cole D Stang; Pierpaolo Turcano; Michelle M Mielke; Keith A Josephs; James H Bower; J Eric Ahlskog; Bradley F Boeve; Peter R Martin; Sudhindra G Upadhyaya; Rodolfo Savica
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 3.  "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.

Authors:  Ján Necpál; Miroslav Borsek; Bibiána Jeleňová
Journal:  Neurol Sci       Date:  2021-09-17       Impact factor: 3.307

4.  EFhd2 brain interactome reveals its association with different cellular and molecular processes.

Authors:  Ahlam S Soliman; Andrew Umstead; Tessa Grabinski; Nicholas M Kanaan; Andy Lee; John Ryan; Jared Lamp; Irving E Vega
Journal:  J Neurochem       Date:  2021-10-03       Impact factor: 5.546

5.  TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model.

Authors:  Eric Shao; Che-Wei Chang; Zhiyong Li; Xinxing Yu; Kaitlyn Ho; Michelle Zhang; Xin Wang; Jeffrey Simms; Iris Lo; Jessica Speckart; Julia Holtzman; Gui-Qiu Yu; Erik D Roberson; Lennart Mucke
Journal:  Sci Transl Med       Date:  2022-04-27       Impact factor: 19.319

6.  Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons.

Authors:  Lucia S Capano; Chihiro Sato; Elena Ficulle; Anan Yu; Kanta Horie; Ji-Sun Kwon; Kyle F Burbach; Nicolas R Barthélemy; Susan G Fox; Celeste M Karch; Randall J Bateman; Henry Houlden; Richard I Morimoto; David M Holtzman; Karen E Duff; Andrew S Yoo
Journal:  Cell Stem Cell       Date:  2022-06-02       Impact factor: 25.269

7.  Truncated Tau caused by intron retention is enriched in Alzheimer's disease cortex and exhibits altered biochemical properties.

Authors:  Zhen-Kai Ngian; Yow-Yong Tan; Ching-Thong Choo; Wei-Qi Lin; Chao-Yong Leow; Shan-Jie Mah; Mitchell Kim-Peng Lai; Christopher Li-Hsian Chen; Chin-Tong Ong
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-06       Impact factor: 12.779

Review 8.  The Cryo-EM Effect: Structural Biology of Neurodegenerative Disease Aggregates.

Authors:  Benjamin C Creekmore; Yi-Wei Chang; Edward B Lee
Journal:  J Neuropathol Exp Neurol       Date:  2021-06-04       Impact factor: 3.148

9.  Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology.

Authors:  Joshua D Cho; Yoon A Kim; Elizabeth E Rafikian; Mu Yang; Ismael Santa-Maria
Journal:  Front Behav Neurosci       Date:  2021-05-21       Impact factor: 3.558

Review 10.  "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.

Authors:  Yuxing Xia; Stefan Prokop; Benoit I Giasson
Journal:  Mol Neurodegener       Date:  2021-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.